Skip to main content
Terug
Watch Compare

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Datakwaliteit: 83%
RVPH
NASDAQ Manufacturing Chemicals
€ 0,89
▲ € 0,03 (3,35%)
6 months return
—
Momentum
Neutral
ROE
-971,25%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-971,25%
Onder sectorgemiddelde (-54,68%)
ROIC-748,32%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Onder sectorgemiddelde (0,30)
Current Ratio1,39
Interest Coverage-1507,24

Waardering

PE (TTM|NTM)
-0,55 | -0,93
Boven sectorgemiddelde (-1,49)
P/B Ratio2,40
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -24,59 M

Price History

Financiële Trends

Koersdoel Analisten

5 analisten
Buy
+6474.8%
upside to target
Huidig
€ 0,89
Consensus Target
€ 58,20
€ 1,00
Laag
€ 140,00
Hoog
Vooruitzicht
Forward K/W
-0,93
Forward WPA
-€ 0,83
Omzet Sch.
0,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 0,93 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 2,60 -€ 2,40 -€ 1,20 -€ 5,19 — —
Estimate -€ 3,65 -€ 2,20 -€ 1,94 -€ 1,07 -€ 0,93 -€ 0,96
Verrassing +28,77% -9,09% +38,24% -386,56% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -971,25% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -19,86 M
ROE -971,25% ROA -153,00%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -24,59 M
ROIC -748,32% FCF Growth (3Y) N/A

Safety

D/E: 0,00 · Current: 1,39
Debt / Equity 0,00 Current Ratio 1,39
Interest Coverage -1507,24 Asset Turnover N/A
Working Capital 3,77 M Tangible Book Value 4,55 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,55 · EV/EBITDA: N/A
P/E Ratio -0,55 Forward P/E -0,93
P/B Ratio 2,40 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -225,18%
Market Cap 10,92 M Enterprise Value -2,26 M

Per Share

EPS: N/A · FCF/Share: -1,92
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -1,92 OCF / Share -1,92
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 123,81% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 123,81%
SBC-Adj. FCF -26,72 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -19,86 M -29,92 M -39,26 M -24,34 M -8,52 M
EPS (Diluted) — — — — —
Gross Profit — — — — —
Operating Income -20,20 M -30,80 M -39,50 M -24,31 M -10,10 M
EBITDA — — — — —
R&D Expenses 11,71 M 22,91 M 31,42 M 18,95 M 4,85 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 13.402,0 18.497,0 — — 0,0
Income Tax 18.889,0 19.514,0 16.949,0 20.777,0 8.281,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15,92 M 15,50 M 23,70 M 18,92 M 31,40 M
Total Liabilities 7,28 M 14,69 M 17,98 M 6,61 M 2,72 M
Shareholders' Equity 8,65 M 812.572,0 5,72 M 12,32 M 28,69 M
Total Debt 406.875,0 458.154,0 — — —
Cash & Equivalents 14,44 M 13,48 M 23,37 M 18,52 M 29,69 M
Current Assets 15,10 M 14,68 M — — —
Current Liabilities 7,28 M 14,60 M 17,18 M 6,04 M 2,34 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,6 -1,5
P/B 2,4 1,6
ROE % -971,3 -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E 0,0 0,3